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Drug-resistant mutations (DRMs) in HIV-1 protease
are a major challenge to antiretroviral therapy.
Protease-substrate interactions that are determined
to be critical for native selectivity could serve as
robust targets for drug design that are immune to
DRMs. In order to identify the structural mechanisms
of selectivity, we developed a peptide-docking algo-
rithm to predict the atomic structure of protease-
substrate complexes and applied it to a large and
diverse set of cleavable and noncleavable peptides.
Cleavable peptides showed significantly lower ener-
gies of interaction than noncleavable peptides with
six protease active-site residues playing the most
significant role in discrimination. Surprisingly, all six
residues correspond to sequence positions associ-
ated with drug resistance mutations, demonstrating
that the very residues that are responsible for native
substrate specificity in HIV-1 protease are altered
during its evolution to drug resistance, suggesting
that drug resistance and substrate selectivity may
share common mechanisms.
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) protease is
responsible for the processing of Gag and Pol polyproteins,
making it critical for viral assembly and maturation and an
important target for antiretroviral therapies. The ten Federal
Drug Administration-approved protease inhibitors are substrate
mimics that resulted from structure-based drug design efforts of
the pharmaceutical industry. The efficacy of these drugs is signif-
icantly hampered by the emergence of drug-resistant mutations
(DRMs) in HIV-1 protease that are thought to preferentially alter
drug binding over substrate binding to the protease. Under-
standing the structural mechanisms of molecular recognition
between HIV-1 protease and its substrates will be critical to
the development of a second generation of protease inhibitors
in the treatment of HIV-1 infection.
HIV-1 protease is an aspartyl protease dimer that processes
the Gag and Pol polyproteins at ten cleavage sites (hereafter1636 Structure 17, 1636–1648, December 9, 2009 ª2009 Elsevier Ltreferred to as endogenous substrates) by recognizing an
8-residue stretch surrounding the cleavage site. By convention,
these substrate residues are denoted P4-P3-P2-P1-P10-P20-
P30-P40, where the scissile bond lies between the P1 and P10
residues. Substrate specificity of HIV-1 protease has been
studied extensively; large databases of cleavable and noncleav-
able peptides have been assembled (Chattopadhyay et al.,
1992; Hellen et al., 1989; Oswald and von der Helm, 1991;
Riviere et al., 1991; Tomasselli et al., 1993; Tomaszek et al.,
1992; Tozser et al., 1991) and the sequences for the ten endog-
enous substrates have been identified (Debouck et al., 1987).
Sequence-based methods including artificial neural networks
and support vector machines have been developed to discrimi-
nate between cleavable and noncleavable peptides (Kim et al.,
2008; Kontijevskis et al., 2007b; You et al., 2005). From these
sequence-based methods in conjunction with experimental
studies (Bagossi et al., 2005; Eizert et al., 2008; Ridky et al.,
1996), a complex picture of HIV-1 protease selectivity has
emerged. With the exception of two relatively common
sequence motifs at P1-P10, aromatic-proline (Aro-P) and hydro-
phobic-hydrophobic (H4-H4)(Beck et al., 2002), there are few
salient features in the sequences of cleavable peptides and
a high degree of interdependence of various peptide residues
(Kontijevskis et al., 2007b). In an impressive study by Kontijev-
skis et al. (2007a), a statistical model developed from a large
database of cleavable and noncleavable peptides for nine
different retroviral proteases identified a number of physico-
chemical relationships between peptide and protease residues
that accurately define and predict cleavability. Ultimately, purely
sequence-based methods, can, at best, implicate, but not
explicitly model, the underlying structural and energetic mecha-
nisms of substrate selectivity that are essential for drug design.
The structural details of protease-substrate interactions have
been characterized through crystallization of HIV-1 protease in
complex with various substrates (Prabu-Jeyabalan et al., 2000,
2002; Tie et al., 2005). Prabu-Jeyabalan et al. crystallized six of
the ten endogenous substrates in complex with a de-activated
HIV-1 protease and proposed the substrate envelope hypothesis
to explain HIV-1 protease selectivity (Prabu-Jeyabalan et al.,
2000, 2002). They observed that all six substrate peptides con-
formed to a common volume within the protease active site
despite significant diversity in their sequences, and theorized
that substrate selectivity is determined primarily by whether
a given peptide sequence is able adopt a low-energyd All rights reserved
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This hypothesis was evaluated in the context of HIV-1 protease
inhibitors, and it was found that the inhibitors also conform to
the substrate envelope. More interestingly, the areas of the
active site where the inhibitor protruded from the envelope,
and consequently formed non-substrate-like interactions with
the protease, were adjacent to DRM residue positions (Chellap-
pan et al., 2007a; King et al., 2004). Subsequent design of small
molecules that fit exclusively within the substrate envelope led to
tight binding inhibitors that showed low to moderate tolerance of
DRMs (Altman et al., 2008a; Chellappan et al., 2007b; Surleraux
et al., 2005).
Despite the prevalence of sequence-based methods
modeling substrate discrimination, and the apparent success
of the substrate envelope hypothesis in inhibitor design, there
is a dearth of structure-based methods for modeling HIV-1
protease selectivity. Kurt et al. used a coarse-grained sequence
threading approach with an empirical potential function to
successfully discriminate binders from nonbinders in a small
set of 16 peptides, and identified peptide internal conformational
energy as an important discriminating factor (Kurt et al., 2003).
Ozer et al. used a similar coarse-grained approach to test
binding of a very large set of random sequences, and demon-
strated that some sequence motifs in endogenous substrates
are near-optimal for binding (Ozer et al., 2006). In both these
cases, the lack of atomic resolution in both the structural model
and potential function limit the conclusions that can be drawn
about the structural mechanisms of selectivity. Wang and Koll-
man used molecular dynamics methods to study the differences
between substrate and inhibitor binding (Wang and Kollman,
2001). In peptide design, Altmen et al. successfully designed
tighter-binding single and double mutants from the substrate
peptide RT-RH using a atomic-resolution computational design
algorithm, but did not address the issue of selectivity (Altman
et al., 2008b). Finally, none of these previous studies, bioinfor-
matic or structure based, have systematically explored the role
of protease active-site residues in selectivity, which is vital given
that some of these residues are frequently mutated in drug-resis-
tant viral strains.
The present study focuses on developing an atomic-resolution
structural model of protease specificity through computational
peptide docking and identifying the underlying mechanisms of
substrate specificity by calculating the free energy contributions
of each protease and peptide residue to the binding of cleavable
and noncleavable peptides. Active-site residue interactions that
are determined to be essential for native substrate selectivity
could serve as robust targets for drug design because of their
central role in protease function. Finally, an atomic-resolution
structural model will enable us to explicitly test the substrate
envelope hypothesis in the context of substrate selectivity. Given
the promising results of drug designmethods implicitly based on
this hypothesis, any additional insight into the substrate enve-
lope hypothesis may yield new avenues for HIV drug research.
RESULTS
Structure Prediction of Protease-Substrate Complexes
Accurate structure prediction of the protease-peptide complex
from a given peptide sequence is critical to subsequent energyStructure 17, 1636–1calculations thatmodel specificity. A comparison of the six previ-
ously crystallized substrates shows that there are small, but
significant, differences in their peptide backbone conformations
(Prabu-Jeyabalan et al., 2002). In order to accommodate these
backbone conformation changes, we developed a novel flexible
peptide-docking algorithm within RosettaDock (Chaudhury and
Gray, 2008; Gray et al., 2003) (flowchart of algorithm illustrated
in Figure 1) and compared it with fixed backbone/side-chain
packing methods traditionally used to study peptide/protein
design and specificity (Altman et al., 2008b; Humphris and
Kortemme, 2007; Sammond et al., 2007). We validated these
methods by comparing the accuracy of the structure predictions
on the six endogenous substrates for each of the crystal struc-
tures that have been determined (Prabu-Jeyabalan et al., 2002).
Table 1 compares the accuracy of the peptide-docking algo-
rithm and the fixed-backbone/side-chain packing method in
recovering the crystal structure of the protease-substrate com-
plex as a measure of the fraction of native residue-residue
contacts recovered (fnat) and root mean square (rms) of interface
residues (Irms). The binding energy of the protease-peptide
complex (DEbinding), as determined by RosettaDock, is also listed
(Wang et al., 2007). The peptide docking predicted all six HIV-1
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Figure 1. Peptide-Docking Algorithm
Flow chart of the Monte-Carlo minimization algorithm for peptide docking.
Table 1. Structural Prediction Accuracy Using Side-Chain
Packing and Peptide Docking
Rotamer Packing Peptide Docking
Name fnat Irms(A˚) DEbinding fnat Irms(A˚) DEbinding
CA-p2 0.82 0.53 8.8 0.87 0.47 12.5
MA-CA 0.66 0.78 8.6 0.71 0.73 11.8
p2-NC 0.67 0.55 10.2 0.79 0.34 13.6
p1-p6 0.59 1.1 10.3 0.68 1.0 13.3
RT-RH 0.75 0.65 10.5 0.84 0.49 13.8
RH-IN 0.66 1.3 10.8 0.75 1.1 15.1648, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1637
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HIV-1 Protease Specificity through Peptide DockingFigure 2. Protease-Peptide Complex Structure Prediction
The structure predictions for the peptides (A) RT-RH, (B) MA-CA, and (C)
RH-IN. The crystal structure of each complex is shown in gray with the peptide
inmagenta. The predicted structure is coloredwith the HIV-1 protease dimer in
green and cyan and the peptide substrate in orange. Active site and substrate1638 Structure 17, 1636–1648, December 9, 2009 ª2009 Elsevier Ltprotease-substrate crystal structures towithin 1.1 A˚ rmsdeviation
(rmsd) with at least 68% of native contacts recovered. The fixed-
backbone method performed marginally, but consistently, less
accurately thanpeptidedocking in fnat and Irms.More importantly,
the peptide-docking structures showed significantly more favor-
able binding energies than fixed-backbone structures due to
a greater number of hydrogenbonds andVanderWaals contacts.
In a number of cases (CA-p2, p2-NC, p1-p6), key interactions
noted by Prabu-Jeyabalan et al. (2002), such as the side-chain
hydrogenbondsbetweenP20 and theproteaseD30or an intramo-
lecular hydrogen bond between P2 and P10, are absent in the
fixed-backbone structures but are recovered in peptide docking.
These results demonstrate that small backbone movements are
necessary to recover key protease-substrate interactions.
The structural models generated from peptide docking are
compared with their respective crystal structures in Figure 2,
for the representative cases of RT-RH,MA-CA, andRH-IN. Over-
all, the peptide conformation of residues P3-P30 is accurately
recovered for both the backbone and side chains. These resi-
dues are the most conformationally invariant among known
protease-substrate structures (Prabu-Jeyabalan et al., 2002),
most likely because they are deeply buried within the sub-
strate-binding site and thus the most highly restricted. P4 and
P40 are less accurately recovered, which can be attributed to
more conformational freedom in these positions, which has
been observed experimentally. In a number of crystal structures,
either the P4 or P40 residues is partially disordered or has high
thermal factors (Prabu-Jeyabalan et al., 2002). The only readily
observable feature in protease-substrate crystal structures that
is absent in the predicted structures is the alternate conforma-
tion of the P3-P4 backbone in the substrates RH-IN (Figure 2C)
and p1-p6 (Prabu-Jeyabalan et al., 2002).
Energetic Discrimination of Cleavable Peptides
Following the accurate prediction of the protease-substrate
complexes for the six known crystallized structures, the test
set was expanded to 69 known cleavable peptides and 43 non-
cleavable peptides, including 4 known endogenous substrates
(NC-p1, TF-PR, PR-RT, AutoP) for which no crystal structures
have been determined. We used the flexible peptide-docking
algorithm to generate structural models for each of the 112
peptides for subsequent energy calculations.
For each structural model, the individual residue energies and
total energy of the protease-peptide complex was calculated.
Figure 3A presents a histogram of the total energies for all 112
substrates and shows a separation between the energies of
cleavable peptides and noncleavable peptides, with some over-
lap. Over 40% of cleavable peptides have lower energy than all
but3% of noncleavable peptides, while over 35% of noncleav-
able peptides have higher energy than all but 5% of cleavable
peptide. AWelch’s t test confirms that there is a significant differ-
ence in the distribution of the total energy between cleavable and
noncleavable peptides (p < 106) suggesting that structural
prediction with the peptide-docking algorithm followed by
energy calculations using the RosettaDock energy function
accurately captures, to some degree, HIV-1 protease selectivity.
residues are shown as sticks. P4 is the peptide residue on the bottom-left, P40
is the peptide residue at the top-right.d All rights reserved
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Figure 3. Energy Distributions of Cleavable and Noncleavable Peptides
Histograms of energies summed over different subsets of residues in the peptide-protease complex for cleavable (blue) and noncleavable (red) peptides.
(A) Energies from all active-site and peptide residues.
(B) Energies from peptide residues alone.
(C) Energies from active-site DRM-associated residues (protease residues 23, 30, 47, 48, 50, 76, 82, 84).
(D) Energies from all active-site residues not associated with DRMs.A similar trend is seen with just the peptide energies alone
(Figure 3B), at a lower p value (p < 104), indicating that protease
residue energies are improving overall discrimination.
Identification of Substrate Specificity Trends
from the Model
In order to further validate that ourmodel was capturing the ener-
getics of substrate specificity in HIV-1 protease, we sorted the
protease-peptide complexes by energy, determined the relative
probabilities of finding certain amino-acid types at each peptide
position from P3-P30 between high-energy and low-energy
peptides, and compared the results with previous experimental
and bioinformatics studies. Amino acids were categorized into
the following overlapping sets: small, hydrophobic, aromatic,
b-branched, charged, and polar. Table 2 lists the log of the rela-
tive probabilities (Plow_energy/Phigh_energy) for each subsite, a
minimum threshold of ± 0.25 was set, outside of which a trend
was deemed significant.Structure 17, 1636–16Overall there is large agreement with the amino acid type
trends from our model with those previously determined for
HIV-1 protease. At P1 and P10, the single most favorable feature
is aromatic residues, followed by hydrophobic residues. These
residue types are typically themost prominent feature in bioinfor-
matics analyses of cleavable peptide sequences (Kontijevskis
et al., 2007b; You et al., 2005) and experimental mutations of
cleavage sites (Eizert et al., 2008), and they constitute 17 of 20
P1/P10 positions among endogenous substrates (Prabu-Jeyaba-
lan et al., 2002). P2, and to a lesser degree P20, shows a strong
preference for b-branched residues, which has been demon-
strated both clinically (Ho et al., 2008) and experimentally (Alt-
man et al., 2008b; Dauber et al., 2002; Prabu-Jeyabalan et al.,
2004) and reflected in the endogenous substrates where 8 of
20 P2/P20 positions have b-branched residues. P3 is notable
for favoring charged and polar amino acids in our model, and
corresponds with the fact that it is the most charge/polar friendly
peptide residue among the endogenous sequences. P3 is also48, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1639
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position to contain an aromatic residue, which agrees with its
favorable score for aromatic residues in the model.
Among the features disfavored at the respective substrate
positions, the most prominent is that of b-branched groups at
P1 and P10, charged groups at any position between P2-P10,
and aromatic residues at P2 and P20. These trends agree well
with rules for identifying noncleavable peptides identified by
Kontijevskis et al. (2007b). The most significant discrepancy
between the residue-type trends observed in the model and
experimental data is the disfavoring of polar residues at P2 in
the model, where experimentally, the polar Asn is favored in
this position (Bagossi et al., 2005). Overall, the agreement of
the purely structure-based model of specificity with the trends
observed in both endogenous substrates and in bioinformatics
analyses of cleavable and noncleavable peptides suggests that
the model accurately captures substrate specificity.
Identification of Specificity-Determining Residues
Because the total energy, taken as the sum of the individual
residue energies for the peptide and active-site protease resi-
dues, successfully discriminates cleavable peptides and also
recovers key sequence features for cleavability, we next exam-
ined whether any individual residues in the complex were
predominately responsible for the observed selectivity. Toward
that end, we applied a Welch’s t test on each residue energy
and classified residues as ‘‘specificity-determining residues’’ if
the mean difference in energies between cleavable and non-
cleavable peptides was at least 0.2 kT and the p value was at
least p < 0.05.
Table 3 lists the specificity-determining residues in the
protease and peptide and their respective p values. Among the
34 active-site protease active site residues, fivewere determined
to be significant at p < 0.01 (D300, I470, L76, V82, I840), and an
additional sixth was found to be significant at p < 0.05 (G480).
Among the eight peptide residues, three were found to be signif-
icant at p < 0.01 (P1-P20), and an additional fifth was found to be
significant at p < 0.05 (P30). Taking the sum of energies of the
specificity-determining residues and applying a Welch’s t test
shows a difference between cleavable and noncleavable
peptides at p < 1011 while the sum of energies from all other
residues shows a difference at p < 0.01, indicating that the statis-
Table 2. Residue Type Selectivity at Each Subsite as
ln(Plow_energy/Phigh_energy)
Residue Small Hydrophobic Aromatic b-Branched Charged Polar
P3 0.25 0.27 +0.69 — +0.25 +0.36
P2 +0.41 +0.79 <<0.0a +1.16 1.39 1.19
P1 — +0.27 +1.30 <<0.0a 1.20 —
P10 0.37 +0.39 +2.64 0.81 <<0.0a —
P20 +0.29 — <<0.0a +0.41 — —
P30 +0.27 — >>0.0a +0.47 — —
a ‘‘<<0.0’’ indicates no low-energy peptides contained a given residue
type at a given position; ‘‘>>0.0’’ indicates no high-energy peptide con-
tained a given residue type at a given position; ‘‘— ’’ indicates minimum
threshold of ln(Plow_energy/Phigh_energy) was not met, indicating no signifi-
cant difference between low- and high-energy binders.1640 Structure 17, 1636–1648, December 9, 2009 ª2009 Elsevier Lttical approach was successful in isolating the residues primarily
responsible for substrate selectivity in this model.
Figure 4 illustrates the spatial position of the specificity-deter-
mining residues in the protease active-site. The protease speci-
ficity-determining residues largely cluster around the P2-P20
subsites, indicating the importance of P2-P20 in substrate spec-
ificity. V82 and I840 are found in both the P10/P1 and P2/P20
subsites, respectively, whereas L76 is in the P2 subsite and
I470 is in the P20 subsite. The high significance of peptide resi-
dues P1-P20 in substrate discrimination confirms this observa-
tion within themodel. G480 is the only protease residue not found
in the P2-P20 subsites, and it shows a relatively weaker signifi-
cance in the P30 subsite, along with P30. Overall, the relative
significance of peptide subsites (P1/P10 > P20 > P30) agrees
with previous bioinformatics (Kontijevskis et al., 2007b) and
experimental studies (Bagossi et al., 2005; Eizert et al., 2008).
The goal of this study was to identify specificity determinants
that were critical to native substrate selectivity to serve as
potential targets for drug design, but, surprisingly, all six of the
protease specificity-determining residues were in sequence
Table 3. Specificity-Determining Residues
Protease Residue p Value DRMs
D300 p < 0.001 N
L76 p < 0.001 V
I470 p < 0.001 V,A
V82 p < 0.01 A,T,F,S,L
I840 p < 0.01 V,A,C
G480 p < 0.05 V,M
Substrate Residue p Value
P1 p < 105
P10 p < 0.001
P20 p < 0.01
P30 p < 0.05
L76
P4 P3
P2
P1
P1’
V82
P2’
P3’
G48’
I47’
D30’
I84’
P4’
Figure 4. Specificity-Determining Residues in the Protease-
Substrate Complex
Residues that were significant at p < 0.001 are colored red, those that were
significant at p < 0.01 are colored orange, and those that were significant at
p < 0.05 are colored yellow. Protease residues are shown in sticks, peptide
residues shown as spheres.d All rights reserved
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mutations (Rhee et al., 2003). Figures 3C and 3D show histo-
grams for the energy taken as the sum of active-site residues
associated with DRMs (L23, D30, L32, G48, I47, I50, L76, V82,
I84 for both chains in the protease) and compares it with the
sum of non-DRM protease residues for cleavable and noncleav-
able peptides. The DRM-associated residues are much stronger
discriminators of cleavable peptides (p < 103) than non-DRM
residues (p < 0.01). These findings demonstrate that the very
residues most responsible for substrate selectivity are the ones
that are mutated in drug resistance, suggesting that HIV-1 alters
its protease substrate specificity when evolving drug resistance.
Structural Mechanisms of Specificity-Determining
Residues
The structural mechanism of substrate discrimination for these
specificity-determining residues was primarily through steric
interactions within the protease-substrate complex. Figure 5
shows a histogram of the individual residue energies accompa-
nied by the structures of representative cleavable and noncleav-
able peptides for four of the six specificity-determining residues.
In the case of I470 (Figure 5A), the primarily energetic component
of discrimination was EVdW and EDun (both at p < 0.01) due to
steric interactions with the P20 side chain. Likewise, in L76 (not
shown), the most significant discrimination was also in the
EVdW and EDun components (p < 0.05 and p < 0.01, respectively)
due to interactions with the side chains from P2 and P4. In I840
(Figure 5B), discrimination is due primarily to EDun (p < 0.05), as
steric interactions from the side-chain atoms of P1 and P20 force
the I840 side chain to adopt unfavorable conformations. In many
cases these steric clashes were from the Cg methyl group in
b-branched side chains at P1. A more complex mechanism
emerges for V82 (Figure 5C), where EDun is the most responsible
for discrimination (p < 0.01). Here, side-chain atoms of P10 and
P2 force the I84 into side-chain conformations that lead to steric
clashes with the V82 side chain, forcing it to adopt unfavorable
conformations. These latter two examples demonstrate a net-
work of steric interactions between P1-P20 and P10-P2 subsites,
that spans more than 10 A˚, from the Ca of P2/P20 to the Cb of
V82/V820.
In two specificity-determining residues, D300 and G4800
hydrogen bonding and solvation energy played a significant
role in discrimination. In G480, the sum of the hydrogen bonding
energy and solvation energy (EHbond+Esolv) was highly significant
(p < 0.001). In cleavable peptides, the backbone oxygen of G480
forms a hydrogen bond with the backbone amide of P30. By
contrast, noncleavable peptides are often characterized by the
presence of an unsatisfied backbone hydrogen bond that is
not exposed to solvent at this position. In D300 (Figure 5D),
EVdW, EDun, Esolv, and EHbond all play a significant role in discrim-
ination (p < 0.05). Discrimination at this position is a result of two
factors: steric interactions between D30 with P20 and P40 side
chains, and hydrogen bonding of the D300 carboxyl group with
either the solvent, the protease (through R8 and N880), or the
peptide (through P20 or P40).
Among the substrate residues, residue energies for P1, P10,
P20, P30 were found to be significantly increased for noncleav-
able peptides over cleavable peptide. For P1, P10, and P20 this
increase was primarily the result of increased EVdW and EDun,Structure 17, 1636–1because noncleavable peptides had residues that exhibited
steric clashes and/or adopted unfavorable side-chain conforma-
tions. For P1, there was an additional effect of EHbond+Esolv
energy terms (p < 0.001), that favored residues with low solvation
energy, such as hydrophobic residues, as well as uncharged
residues that can form side-chain or backbone hydrogen bonds
with carbonyl oxygen of G27. In our data set, Asnwas the only P1
residue that could reliably form this hydrogen bond, perhaps
explaining why it is the only polar residue at P1 among the
endogenous substrates (Prabu-Jeyabalan et al., 2002). At P30,
there is an effect of EHbond (p < 0.05) that is due to backbone-
backbone hydrogen bond formation with G480. Finally, at P20,
among the 75 peptides with polar residues at this position, there
was an additional effect of EHbond+Esolv energy terms (p < 0.01),
due to hydrogen bond formation with either the side-chain amide
of K450 (in the case of Glu) or side-chain carboxyl and backbone
amide of D300 (in the case of Gln). Hydrogen bonding between
D300 and the P20 side chain has been observed in a number of
protease-substrate crystal structures (Tie et al., 2005) and
demonstrated to be important for specificity (Lin et al., 2003).
Evaluating the Substrate Envelope Hypothesis
The substrate envelope hypothesis states that the protease
selects cleavable substrates on the basis of their ability to fit
within a given consensus volume (Prabu-Jeyabalan et al.,
2002). Although this hypothesis was evaluated in the context of
protease inhibitors (Chellappan et al., 2007a), it has never before
been evaluated in the context of substrate peptides. In evalu-
ating this hypothesis, we look at two factors: first, whether it is
necessary for a cleavable peptide to fit within the substrate enve-
lope, and second, whether being able to fit inside this volume is
sufficient to determine cleavability.
We defined a substrate envelope consisting of the 70% con-
sensus volume (King et al., 2004) from the structural models
for the ten endogenous substrates, as the volume of all heavy
atoms within the Van der Waals radius of another heavy atom
for at least 7 other substrate peptides. Figure 6 illustrates the
degree to which cleavable and noncleavable peptides protruded
from the substrate envelope at subsites P2-P20. Overall, more
heavy atoms (Natoms) protrude from the substrate envelope for
noncleavable than cleavable peptides (p < 105), but there
were a substantial number of noncleavable peptides that
showed minimal protrusion. Approximately 90% of cleavable
peptides had at most two protruding heavy atoms between
P2-P20, compared with 40% of noncleavable peptides. These
results suggest that although staying within the substrate enve-
lope is necessary for the cleavability of a peptide, it is not suffi-
cient to determine cleavability.
Because the substrate envelope hypothesis is based on an
active-site volume that is governed by steric and conformational
energies, we tested whether the degree of protrusion from the
substrate envelope of a given peptide was related to the energy
of the protease-peptide complex. Figure 6B shows a correlation
(R2 = 0.37) between the total energy of the complex and the
number of protruding heavy atoms, demonstrating that the
substrate selectivity described by the substrate envelope
hypothesis is largely related to the energiesmodeled in our study.
The spatial positions of the protease specificity-determining
residues are immediately adjacent to regions of the substrate648, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1641
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HIV-1 Protease Specificity through Peptide Dockingenvelope with a large number of protrusions in noncleavable
peptides (Figure 6A), suggesting these residuesplayan important
role in maintaining the appropriate shape of the substrate enve-
lope for native substrate recognition. This spatial relationship
bears a striking resemblance to the spatial positionofDRM-asso-
ciated residues in the substrate envelopewith regards to inhibitor
interactions (Chellappan et al., 2007a; King et al., 2004). In both
cases, these residues are immediately adjacent to regions of
substrate peptides and drug molecules that fall outside of the
envelope. Additionally, every residue identified in the aforemen-
tioned studies as active-site DRM residues are identified in the
present study as a specificity-determining residue.
Finally, we attempted to capture the promiscuity of HIV-1
protease by defining a ‘‘binding envelope,’’ which is based on
the 70% consensus volume of all cleavable peptide structure
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Figure 6. Evaluation of the Substrate Envelope Hypothesis
(A) Peptide residues P2-P20 are shown for cleavable (left) and noncleavable
(right) peptides. Peptide side-chain atoms are shown as sticks (magenta),
atoms that protrude from the substrate envelope are shown as yellow spheres.
Protease specificity-determining residues are shown as sticks (green and
cyan).
(B) Plot of number of heavy atoms that protrude from the substrate envelope
(Natoms) versus the energy of the protease-peptide complex, for cleavable
(red) and noncleavable (blue) peptides.Structure 17, 1636–1in the data set, and compare it with the substrate envelope.
Figure 7 illustrates the binding envelope along with the substrate
envelope and the inhibitor volume, defined as the Van der Waals
volume of all heavy atoms in inhibitors Nelfinavir, Saquinavir,
Indinavir, Ritonavir, Amprenavir, Lopinavir, and Atazanavir. A
comparison of these three volumes reveals three significant
characteristics. First, the binding envelope is substantially larger
than the substrate envelope, indicating significantly greater
structural diversity among all binders than among the ten endog-
enous substrates. Second, as previous studies have noted
(Chellappan et al., 2007a; King et al., 2004), there are substantial
portions of the inhibitor volume that fall outside of the substrate
envelope, especially around the regions of DRM residues I50,
V82, I84, D30. Finally, the regions of the inhibitor volume that
fall outside of the substrate envelope are largely contained within
the binding envelope. This is especially clear in the aforemen-
tioned DRMs.
Other Structural Determinants of Specificity
Although binding energy models and the substrate envelope
hypothesis are largely accurate in defining the cleavability of
a given peptide sequence, they are, to some degree, insufficient,
because the activity of HIV-1 protease to a particular substrate is
a function of both the catalytic rate (kcat) and dissociation
constant (Km). Although differences in the energies of
protease-substrate interactions may affect both kcat and Km,
kcat is additionally affected by other features that are critical to
enzymatic catalysis, such as active-site bond geometry, that
may be essential to defining substrate specificity.
In the reaction mechanism of an aspartyl protease, one cata-
lytic aspartate (D25) acts as a general base, deprotonating
a water molecule that subsequently hydrates the carbonyl group
about the scissile peptide bond to form a tetrahedral interme-
diate, and the second aspartate acts (D250) as a general acid,
facilitating peptide-bond cleavage. We measured the geometry
of peptide carbonyl group with respect to the carboxyl groups
of the catalytic aspartates as the angle between the C-O
bond vector of P1 and Od2-Od2 vector between D25 and D25
0
(qactive-site). This angle reflects the orientation of the bond geom-
etry of the carbonyl carbon of P1 with respect to the catalytic
aspartates that catalyze its hydration. In all ten endogenous
substrates and approximately 90% of cleavable peptides,
qactive-site ranged from 120
 to 150, compared with approxi-
mately 50% of noncleavable peptides (see Figure S1 available
online).
We observed a significant subpopulation of noncleavable
peptides (30%) that had a qactive-site between 60 and 100.
Figure S1 illustrates the active-site geometry for two representa-
tive cases with qactive-site at 90
 and 140. The carbonyl oxygen at
qactive-site of 90
 occludes the proposed position of the catalytic
water molecule (Silva et al., 1996), while the same oxygen at
qactive-site of 140
 provides ample space for the water as well asFigure 5. Structural and Energetic Mechanisms of Specificity
Left: Histograms for the individual residue energies for specificity determinant residues (A) I470, (B) I840, (C) V82, and (D) D300 for cleavable (blue) and noncleavable
(red) peptides. Right: Structures of representative cleavable and noncleavable peptides for each specificity-determining residue. The specificity-determining
residue is colored with respect to its residue energy (spectrum from blue to red for low energy to high energy). Important interacting residues as well as the spec-
ificity-determining residues are shown as sticks for the peptide (dark gray) and the protease (light gray). The cleavable peptides selected for illustration are the ten
endogenous substrates, the noncleavable peptides are the ten with the highest residue energy for each respective specificity-determining residue.648, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1643
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Figure 7. Substrate and Binding Envelope in the Protease Active Site
(A) The substrate envelope (red surface) and binding (blue mesh) envelope volumes are illustrated for substrate residues P3-P30. DRM residues 30, 47, 48, 50, 82,
and 84 are shown as sticks.
(B) The inhibitor volume, consisting of the combined volumes of inhibitors Nelfinavir, Saquinavir, Indinavir, Ritonavir, Amprenavir, Lopinavir, and Atazanavir, is
shown in orange.the appropriate geometry for hydration. Furthermore, among the
two most prominent sequence motifs at the P1-P10 positions for
cleavable peptides (Beck et al., 2002), 100%of peptides with the
Aro-P motif (11/11) and 90% of peptides with the H4-H4motif
(46/52) were within the normal range of 120–150, compared
with 60% (31/49) for all other peptides. These results suggest
that specificity, especially at P1 and P10, may be governed, in
part, by the ability of a peptide to adopt the appropriate catalytic
geometry within active site that is not reflected by binding ener-
getics alone.
DISCUSSION
In this study we developed a novel peptide-docking algorithm
that was able to accurately predict the HIV-1 protease-substrate
complex structure at an atomic resolution and recover most of
the important interactions for six previously determined crystal
structures. We then predicted the structures for a large, diverse
set of cleavable and noncleavable peptides, calculated an
approximate free energy of the resulting complex, and showed
significantly more favorable energies among cleavable peptides
than noncleavable peptides. We sorted the peptides based
purely on energy and recovered most major residue-type trends
at P3-P30 identified in previous studies, validating our method as
an accuratemodel of substrate specificity. Finally, through statis-
tical analysis of the individual residue energies in each complex,
we identified several specificity-determining residues that are
predominately responsible for discriminating cleavable peptides.
We found that substrate specificity is largely determined by
residues that cluster around the P2-P30 subsites. Steric interac-
tions between side chains at P2-P20 in noncleavable peptides led1644 Structure 17, 1636–1648, December 9, 2009 ª2009 Elsevier Ltto significantly higher energies in the protease residues L76, V82,
D300, I470, and I840. Hydrogen bonding and solvation energies
played amajor role as well, particularly with D300 andG48. These
results are in broad agreement with bioinformatics-based identi-
fication of specificity-determining residues over a data set of
nine retroviral proteases and corresponding cleavage data
carried out by Kontijevskis et al. (2007a). Using multivariate anal-
ysis using physiochemical descriptors based on the protease
sequences, they also found D30, V82, and I84 to play the major
role in determining cleavage specificity. However, a number of
residues identified in their study were not found to be specificity
determining in the present study (R8, T26, V32, I64, P81, N83,
L90), and vice versa (I47, I48, L76). The reason for this discrep-
ancy is unclear; additional specificity effects of protease resi-
dues observed in the present study may arise indirectly through
the significant intrapeptide cross-dependencies observed in the
study by Kontijevskis et al., or their use of a set of nine retroviral
proteases may bias certain protease residues toward being
specificity-determining for reasons of sequence conservation
and cleavage data availability. Additionally, because Kontijev-
skis et al. analyzed experimental data directly, they may have
captured effects such as protease dynamics or chemical activity
that are beyond the scope of our static structural methods. Given
that our structural approach is completely orthogonal to their
bioinformatics approach, the agreement between the two
studies is encouraging, while the discrepancy is of interest for
further research.
In our model, specificity was a result of both local and nonlocal
structural mechanisms. Local mechanisms conferred specificity
at a given subsite through the energetics of the peptide and
protease residues within that subsite, such as the disfavoringd All rights reserved
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burial of a charged group at P10 in the active site. Nonlocal mech-
anisms conferred selectivity through energetics of peptide and
protease residues at distal subsites or multiple subsites. Exam-
ples of nonlocal mechanisms include P2 side-chains affecting
the energies of the P10 subsite through steric interactions with
I84 and V82 or various combinations of peptide side-chains
leading to unfavorable peptide backbone conformations that
disrupt conserved peptide-protease hydrogen bonds. That no
single sequence motifs appeared to dominate low-energy or
high-energy binders in our study underscores the degree to
which these indirect effects play a major role in determining
cleavability, reflecting the observed interdependence between
peptide sequence positions on cleavable substrates in bioinfor-
matics studies (Kontijevskis et al., 2007b; Ozer et al., 2006).
Finally, we found that effects not captured by the protease-
peptide energies, such as the active-site bond geometries,
may play a major role in specificity as well, potentially explaining
the prevalence of Aro-P and H4-H4 motifs at P1-P10 among
cleavable peptides.
Through this effort, we hoped to identify several specificity-
determining protease residues that would be critical to native
selectivity and thus serve as robust targets for drug design.
This goal was premised on the prevailing theory that drug resis-
tance in HIV-1 protease is the result of mutations that alter inhib-
itor binding without significantly affecting substrate recognition
(King et al., 2004). The unexpected result of the study is that
those residues that are determined to be critical for substrate
recognition are also residues that clinical studies have revealed
to be positions of high-frequency DRMs, which is demonstrated
most clearly by the substantial difference in energies between
cleavable and noncleavable peptides when using only active-
site DRM residue energies in our model. These findings indicate
that active-site DRMs do alter substrate recognition and, more
importantly, imply that drug resistance and substrate recognition
may share common mechanisms.
The importance of DRM residues in substrate selectivity
suggests that any mutations to these residues may alter the
specificity of the protease, perhaps even toward its endogenous
substrates. In fact, experimental evidence has long supported
that native substrate binding can be altered in drug-resistant
variants of HIV-1 protease. Both clinical and in vitro studies
have revealed that many viral variants that display early-stage
drug resistance show significantly decreased viral infectivity,
as a result of decreased or defective protease activity (Mam-
mano et al., 2000; Martinez-Picado et al., 2000; Zennou et al.,
1998). Lin et al. (1995) showed at least a several-fold increase
in the Km of HIV-1 protease binding to peptide substrate
Ca-P2 in several DRMs at positions V82 and D30. Additionally,
a number of studies have observed polymorphisms in the sev-
eral Gag polyprotein cleavage sites, including in response to
decreased activity of drug-resistant protease variants (Doyon
et al., 1996; Ho et al., 2008; Zhang et al., 1997). The most
frequently observed of these cleavage site mutants is the heavily
studied valine to alanine substitution in P2 of NC-p1 found in
patients with the V82A protease mutation, for which a crystal
structure of the complex has been determined (Prabu-Jeyabalan
et al., 2004). Dauber et al. found altered specificity in a peptide-
library cleavage assay for several DRM proteases, most promi-Structure 17, 1636–1nently in the selectivity of b-branched residues at the P2 position
in V82 mutants. Finally, a series of studies on the closely related
feline immunodeficiency virus (FIV) protease found that several
residues that correspond to DRM positions 30, 46, 47, 48, 50,
82, and 84 of HIV-1 protease are responsible for the differences
in specificity between FIV protease and HIV-1 protease (Beck
et al., 2001; Lin et al., 2000; Lin et al., 2003).
We evaluated the substrate envelope hypothesis in the
context of substrate selectivity and found that while it is neces-
sary for a peptide to have a minimal number of protrusions to
be cleavable, it is not sufficient in defining cleavability, because
a significant number of noncleavable peptides also had either
low number or zero protrusions. A residue-type analysis carried
out on the 30 least-protruding and 30 most-protruding sub-
strates (data not shown) revealed markedly different trends
from the aforementioned analysis using low- and high-energy
peptides that are not reflected in bioinformatics studies, most
prominently, and unsurprisingly, that ‘‘small’’ residues play a
dominant role in minimizing protrusions (and consequently
defining cleavability, according to the hypothesis). These find-
ings underscore the limitations of the substrate envelope
hypothesis as amodel for substrate specificity in HIV-1 protease.
However, we found the theory underlying the substrate enve-
lope hypothesis, the use of substrate consensus volumes to
define binding behavior, useful in describing the specificity and
promiscuity of HIV-1 protease. We generated a substrate enve-
lope consisting of the consensus volume of the ten endogenous
substrates, and a binding envelope consisting of the consensus
volume of all cleavable peptides, and found that the binding
envelope was significantly larger than the substrate envelope,
indicating substantially more structural diversity among the set
of all cleavable peptides than in the ten endogenous substrates.
Furthermore, we observed that regions of the active-site with the
greatest disparity between the binding and substrate envelopes,
indicating areas in the active-site where there is the greatest
diversity among all cleavable peptides compared with endoge-
nous substrates, (i.e., greatest ‘‘promiscuity’’) are often immedi-
ately adjacent to DRM residues. These results suggest that the
HIV-1 protease active site is ‘‘primed’’ to develop DRMs where
this structural promiscuity is highest (subject to other constrains,
such as protease stability). An examination of protease inhibitor
volumes shows that heavy atoms in inhibitors often protrude
from the envelope into these areas of high promiscuity, adjacent
to the DRM residues that disrupt their binding. Whether this rela-
tionship between DRM and binding-site structural promiscuity is
a general feature of drug resistance requires further study.
From a methodological perspective, this study represents
a first attempt, to our knowledge, to systematically identify
enzyme specificity determinants through a structure-based
method. Through this approach, we demonstrate that the spec-
ificity-determining residues in HIV-1 protease largely overlap
with active-site residues associated with drug resistance and
expand on the substrate envelope hypothesis to account for
both the specificity and promiscuity of HIV-1 protease, in the
hope that a more complete understanding of its molecular
recognition can yield valuable insight for HIV drug research.
Finally, we intentionally designed the method to be generally
applicable to any enzyme that interacts with peptide substrates
for which a high-resolution structure is known, and a data set of648, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1645
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We are currently exploring its uses in other systems.
We have uploaded the set of 112 structure predictions in
Protein Data Bank format, along with a database containing
a listing of every peptide, its sequence, cleavability, and residue
energies from resulting structure prediction, to our website for
public use (http://graylab.jhu.edu). We believe this study repre-
sents only a fraction of the analyses that can be performed on
this data set, and it is our hope that other groups will be able
use this information in conjunction their own molecular modeling
or statistical techniques to glean additional information about
substrate specificity in HIV-1 protease.
EXPERIMENTAL PROCEDURES
Collecting the Peptide Sequence Data
We relied on several previous publications for peptide sequences that have
been demonstrated to be cleaved by HIV-1 protease (Hellen et al., 1989;
Oswald and von der Helm, 1991; Riviere et al., 1991; Tomasselli et al., 1993;
Tomaszek et al., 1992; Tozser et al., 1991). The ten endogenous substrate
sequences were added to the set of cleavable sequences (Prabu-Jeyabalan
et al., 2002). The majority of noncleavable sequences were collected using
a sliding 8-residue window around cleavage sites of HIV-1 reverse transcrip-
tase, as determined by Tomasselli et al. (1993), from i-8 residues preceding
to i+8 residues flanking the cleavage site i, in increments of 2 residues. Non-
cleavable sequences also included five peptides predicted by Chou (1996)
to have the lowest affinity for the protease. Finally, any peptide sequence
that was identical in over four consecutive positions to any other peptide in
the set was removed to ensure diversity. The final data set contained 69 cleav-
able peptides, including 10 endogenous substrates, and 43 noncleavable
peptide sequences.
Computational Peptide Docking
The goal of peptide docking was to predict the structure of the protease-
substrate complex at an atomic resolution for subsequent energy calculations
(Hao et al., 2008; Prasad et al., 2007; Sood and Baker, 2006). We developed
our own flexible peptide-docking algorithm to restrict the conformational
search to a relatively local search because the end goal is specificity determi-
nation, not structure prediction. The protease structure used for docking was
obtained from the crystal structure of HIV-1 protease bound to the inhibitor
Saquinavir (Krohn et al., 1991). The substrate peptide starting conformation
and rigid-body position was defined from the crystal structure of HIV-1
protease bound to the endogenous substrate p2-NC (Prabu-Jeyabalan
et al., 2002), after its bond lengths and angles were adjusted to ideal values
(Engh and Huber, 1991). This starting substrate conformation ensured that
the scissile peptide bond is in the correct conformation and orientation with
respect to the catalytic active site residues for enzymatic catalysis and is
largely constant across all crystallized peptides (Prabu-Jeyabalan et al.,
2002). A given substrate peptide sequence was then threaded through this
‘‘generic’’ starting structure to create the starting structure for that particular
peptide sequence for docking.
Peptide docking was carried out using a novel algorithm written within the
RosettaDock protein docking software (Chaudhury and Gray, 2008; Gray
et al., 2003; Wang et al., 2007). The protease-peptide complex is represented
entirely in atomic resolution, and the peptide backbone along with the peptide
and protease side chains are perturbed in a Monte Carlo plus minimization-
based algorithm with simulated annealing. A flowchart representing the algo-
rithm is illustrated in Figure 1. The temperature was decreased geometrically
from a starting value of kT = 3.0 to a final value of 0.8. The starting structure
underwent 96 cycles of docking to generate a single structural model, or
decoy, and a total of 500 decoys were generated for each substrate peptide
sequence.
Within each cycle, the peptide undergoes 4 and c perturbations using
a series of ‘‘small’’ moves, which randomly perturb 4 or c of residue i, and
‘‘shear’’ moves, which randomly perturb 4 of residue i and c of residue i-1
(reviewed in Rohl et al., 2004). The magnitude of the perturbation was chosen1646 Structure 17, 1636–1648, December 9, 2009 ª2009 Elsevier Ltdfrom a randomized Gaussian distribution that was scaled linearly with temper-
ature from 20 at the beginning of the docking run to 5.3 at the end. Following
a set of small and shear moves, the peptide backbone torsion angles, rigid-
body position, and peptide and protease side-chain torsion angles were opti-
mized using conjugate gradient-based minimization using the all-atom energy
function. Every cycle the peptide and protease side-chain conformations were
optimized using the ‘‘rotamer trials’’ method as described in (Wang et al.,
2005), and every eighth cycle they were further optimized through a combina-
torial repacking algorithm, as described in Kuhlman and Baker (2000), using an
expanded rotamer library (Dunbrack and Cohen, 1997; Wang et al., 2005). The
energy function used throughout the simulation is the standard docking energy
function used in RosettaDock (Gray et al., 2003), consisting primarily of Van
der Waals, hydrogen bonding, solvation, statistical pair-wise, and side-chain
internal energy terms. The lowest-energy decoy among the 500 generated
for each peptide sequence was selected as the final structural model for
that peptide. Each decoy took approximately 210 s to generate on a single
3.0 GHz Intel Xeon processor; the entire data set for 111 sequences was
generated in approximately 3300 CPU hours.
We compared this flexible peptide docking algorithm with a fixed-backbone
algorithm where the same starting structure was used, the peptide backbone
and rigid body position was held fixed, and the side-chain conformations were
optimized using the same methods as described above.
Energy Calculations
The cleavability of a given substrate peptide is represented as the enzyme
specificity constant toward that substrate, defined as kcat/Km, where kcat is
the rate of product formation and Km is dissociation constant. Differences in
free energy of enzyme-substrate interactions can be related to the specificity
constant by DG = RT ln(kcat/Km) according to transition state theory. In this
study, we approximate the free energy of interaction between the enzyme
and the substrate as the sum of the individual residue energies (Ei) of each
active-site and peptide residue i, for a given structure (struct): DG = SEi(struct).
For each structure, the individual residue energies are calculated as the sum of
five components of the standard RosettaDock energy function: Van der Waals
energy (Ei
VdW), side-chain conformational energy (Ei
Dun), solvation energy
(Ei
solv), hydrogen bonding energy (Ei
Hbond), and a residue reference energy
(Ei
ref): Ei(struct) = Ei
VdW(struct) + Ei
Dun(struct) + Ei
solv(struct) + Ei
Hbond(struct) +
Ei
ref(struct). The Van der Waals energy was represented using a modified Len-
nard-Jones 6-12 potential as described in Gray et al. (2003), the side-chain
conformational energy was represented by statistical potential reflecting the
Dunbrack rotamer probabilities (Dunbrack and Cohen, 1997; Kuhlman and
Baker, 2000), the solvation energy was represented by the Lazaridis-Karplus
Gaussian solvent-exclusionmodel (Lazaridis and Karplus, 1999), the hydrogen
bonding energy was represented by a statistical orientation-dependent poten-
tial (Kortemme and Baker, 2002), and the residue reference energy was repre-
sented by a fitted energy function that describes the unfolded reference state,
as described in Kuhlman and Baker (2000). All energies are listed in arbitrary
units of kT. The total energy was taken as the sum of the individual residue
energies of active-site residues (residues 8, 23, 25, 27, 28, 29, 30, 32, 45,
47, 48, 49, 50, 76, 81, 82, and 84) on both chains in the protease and all
8-peptide residues. This ‘‘free energy’’ approximation implicitly includes the
entropy of the solvent but neglects peptide and protease conformational
entropy.
Identification of Specificity Determinants
We used a Welch’s t test on both the total free energy and on the individual
residue energies between cleavable and noncleavable peptide sequences to
identify significant energetic differences. A threshold of 0.2 kT was set for
the difference of mean values, below which the distribution of energies
between cleavable and noncleavable peptides was considered indistinguish-
able. The t test was conducted assuming unequal sample sizes, unequal
variances, and an alternative hypothesis that cleavable peptides have a
lower energy than noncleavable peptides. We conducted all statistical anal-
yses using the R statistical software package (R Development Core Team,
2004).
A residue was considered a specificity-determining residue if it showed
a significant decrease in energy between cleavable and noncleavable peptides
with at least p < 0.05. We also conducted a jack-knife statistical test toAll rights reserved
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by chance by randomizing the cleavability of a peptide sequence in our data
set and carrying out the statistical protocol 20 times, and found that, on
average, 0.15 residues were significant at p < 0.01 and 0.55 residues were
significant at p < 0.05.
Validation of the Method
We validated the structure prediction accuracy of the peptide docking algo-
rithm by comparing the final structural models of six endogenous substrates
(MA-CA, CA-p2, p2-NC, p1-p6, RT-RH, RH-IN) with their respective crystal
structures (Prabu-Jeyabalan et al., 2002). Structural accuracy was determined
using two measurements, fnat, or the fraction of native residue-residue con-
tacts (defined as two residues in which a heavy atom from one residue is within
5A˚ of a heavy atom from the other) between the protease and peptide that is
recovered in the structure prediction, and Irms, the rms distance of all Ca
atoms within 5A˚ of the protease-peptide interface following an optimal super-
position along those atoms (Mendez et al., 2005).
We validated our modeling of substrate specificity in two ways. First we
tested if there was a significant difference in free energy between cleavable
and noncleavable peptides complexed with the protease using a Welch’s
t test, as described above. Second, we classified each peptide residue ac-
cording to six types: small (G, C, N, S, T, D, A, V, P), hydrophobic (A, V, P,
M, F, L, Y, I, W, C), charged (D, E, H, K, R), polar (T, C, S, N, D, Q, E, K, R,
H, Y, W), aromatic (F, Y, W), and b-branched (V, I, T). We then sorted the
peptides based on free energy of the peptide-protease complex and calcu-
lated relative probability of finding each residue type at each subsite between
the 30 lowest-energy peptides versus 30 highest-energy peptides. We
compared these relative residue type probabilities with those observed in
the literature for cleavable peptides and the endogenous substrates.
SUPPLEMENTAL DATA
Supplemental Data include one figure and can be found with this article online
at http://www.cell.com/structure/supplemental/S0969-2126(09)00410-9.
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